منابع مشابه
Allopurinol-induced DRESS syndrome.
Hyperuricemia is present in approximately 5% of the population, the vast majority of whom are asymptomatic and at no clinical risk. Complications, including renal calculi, uric acid nephropathy and gout, occur in a small proportion of patients. Allopurinol, an analog of hypoxanthine, has been widely used in clinical practice for over 30 years for the treatment of hyperuricemia and gout. Two per...
متن کاملEnoxaparin-Induced DRESS Syndrome
Low-molecular-weight heparins are widely used for the prophylaxis and treatment of venous thromboembolism. However, they can induce adverse skin reactions. The most common reactions are delayed-type hypersensitivity reactions at injection sites. Rare systemic reactions have been reported. We report, to our knowledge, the first case of a drug reaction with eosinophilia and systemic symptoms synd...
متن کاملAllopurinol Induced DRESS Syndrome.
A 45 years old female on allopurinol for 3 months presented with itching, rash, facial oedema and eosinophilia with hepatic and renal dysfunction. Skin biopsy revealed interface dermatitis, suggesting the diagnosis of DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) syndrome.
متن کاملDelayed-onset vemurafenib-induced panniculitis
INTRODUCTION Approved in 2011, vemurafenib is a selective serine/threonine kinase inhibitor directed against the V600E mutation in the BRAF gene. This drug is often used in dermatology as a targeted therapy for metastatic or unresectable melanomas, for which about 50% have this mutation. Other tumors possessing the V600E mutation are targets for this therapy. The commonly reported adverse effec...
متن کاملSuccessful use of dabrafenib after the occurrence of drug rash with eosinophilia and systemic symptoms (DRESS) induced by vemurafenib
DRESS: drug rash with eosinophilia and systemic symptoms INTRODUCTION Vemurafenib and dabrafenib are 2 BRAF inhibitors that are approved by the US Food and Drug Administration for the treatment of metastatic malignant melanoma with BRAF mutation. These drugs improve overalland progression-free survival. Some severe vemurafenib-induced reactions have been reported, which commonly require treatme...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JAMA Dermatology
سال: 2013
ISSN: 2168-6068
DOI: 10.1001/jamadermatol.2013.5278